retatrutide clinical trials brazil Representation of racialised and ethnically diverse populations in multicentre randomised controlled of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps Today, we shared new data

It is considered to be a secondary adverse reaction and is often related to other symptoms a person may experience after the injection

S.ThulesenJ.HareK

Discontinuation of treatment due to gastrointestinal adverse events was more frequent with any dose of tirzepatide (risk ratios ranging from 6.39 to 10.65) or semaglutide (risk ratios ranging from 4.99 to 8.91) compared with placebo (Fig

[1] [3] Beyond glycemic control, these medications slow gastric emptying, which prolongs satiety and reduces appetite through central nervous system pathways

[DOI] [PubMed] [Google Scholar] 53.Ziegler O., Sirveaux M.A., Brunaud L., Reibel N., Quilliot D